Media stories about VolitionRX (NYSEMKT:VNRX) have been trending positive this week, Alpha One reports. Alpha One, a service of Accern, scores the sentiment of press coverage by analyzing more than twenty million blog and news sources. Alpha One ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. VolitionRX earned a media sentiment score of 0.29 on Alpha One’s scale. Alpha One also assigned news headlines about the medical research company an impact score of 0 out of 100, meaning that recent press coverage is extremely unlikely to have an effect on the stock’s share price in the next several days.

Insider Buying and Selling by Quarter for VolitionRX (NYSEMKT:VNRX)

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of VolitionRX in a report on Tuesday, March 14th.

Shares of VolitionRX (VNRX) traded down 3.00% during trading on Friday, reaching $3.23. The company had a trading volume of 56,318 shares. VolitionRX has a 52-week low of $3.05 and a 52-week high of $5.86. The company’s market capitalization is $85.14 million. The firm has a 50-day moving average price of $3.52 and a 200-day moving average price of $4.10.

VolitionRX (NYSEMKT:VNRX) last issued its quarterly earnings data on Thursday, May 11th. The medical research company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.01. On average, analysts predict that VolitionRX will post ($0.55) EPS for the current fiscal year.

WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at

VolitionRX Company Profile

VolitionRx Limited is a clinical-stage life sciences company. The Company is focused on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The Company has developed approximately 30 blood-based assays to detect specific biomarkers that can be used individually or in combination to generate a profile, which forms the basis of a test for a particular cancer or disease.

Receive News & Stock Ratings for VolitionRX Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX Ltd and related stocks with our FREE daily email newsletter.